More than a dozen companies and academic groups are trying to create a vaccine to fight Zika.
One of which, Inovio Pharmaceuticals Inc., recently announced it's "preclinical testing of its synthetic vaccine for the Zika virus induced robust and durable immune responses, demonstrating the potential for a SynCon vaccine to prevent and treat infections from this harmful pathogen."
"With robust antibody and killer T cell responses generated by our vaccine in mice, we will next test the vaccine in non-human primates and initiate clinical product manufacturing," said Dr. J. Joseph Kim, Inovio's President and CEO, in a statement.
The company plans to start human testing by the end of this year.
